Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer

IMPORTANCE: Sipuleucel-T is an immunotherapy that has been approved for use in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). However, sipuleucel-T may not be available to some patients because of logistics, cost, and practice structure....

Descripción completa

Detalles Bibliográficos
Autores principales: Caram, Megan E. V., Ross, Ryan, Lin, Paul, Mukherjee, Bhramar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481456/
https://www.ncbi.nlm.nih.gov/pubmed/31002323
http://dx.doi.org/10.1001/jamanetworkopen.2019.2589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481456/
https://www.ncbi.nlm.nih.gov/pubmed/31002323
http://dx.doi.org/10.1001/jamanetworkopen.2019.2589

Ejemplares similares